Carla Dawn Carroll, MD | |
1559 Watasheamu Rd, Gardnerville, NV 89460-7455 | |
(775) 265-4215 | |
Not Available |
Full Name | Carla Dawn Carroll |
---|---|
Gender | Female |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | 1559 Watasheamu Rd, Gardnerville, Nevada |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1760416028 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 5848 (Nevada) | Primary |
Mailing Address | Practice Location Address |
---|---|
Carla Dawn Carroll, MD 5610 Laurel Road, Carson City, NV 89701 Ph: (775) 885-2981 | Carla Dawn Carroll, MD 1559 Watasheamu Rd, Gardnerville, NV 89460-7455 Ph: (775) 265-4215 |
News Archive
New research is suggesting that using incense for long periods could increase the risk of developing cancers of the respiratory tract.
University of British Columbia researcher Hongshen Ma has developed a simple and accurate device to study malaria, a disease that currently affects 500 million people per year worldwide and claims a million lives.
Mazor Robotics Ltd., the developer of Renaissance, an innovative surgical guidance system and its complementary products, announced today that Lawnwood Regional Medical Center & Heart Institute, located in Ft. Pierce, FL, has purchased its first Renaissance system.
Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced the initiation of a Phase I clinical trial of TRV120027, a titratable i.v. agent designed for the treatment of acute decompensated heart failure. TRV120027 is a biased ligand that targets the angiotensin II type 1 receptor (AT1R) and induces a unique mode of signaling.
› Verified 2 days ago